ATXI(Delisted)
Avenue Therapeutics·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Significant Inflow of Main Funds
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATXI
Avenue Therapeutics, Inc.
A pharmaceutical company that develops an intravenous formulation of tramadol HCI for the treatment of post-operative pain
1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154
--
Avenue Therapeutics, Inc., was incorporated in Delaware on February 9, 2015. The Company is a specialty pharmaceutical company focused on the development and commercialization of intravenous or IV tramadol HCl or IV tramadol for the management of moderately to moderately severe postoperative pain. The Company has an exclusive license to develop and commercialize IV tramadol in the United States and plans to seek other products developed in the acute/critical care hospital market beyond Type IV tramadol.
Company Financials
EPS
ATXI has released its 2025 Q2 earnings. EPS was reported at 0.11, versus the expected 0, beating expectations. The chart below visualizes how ATXI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
